Cargando…
miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44
Introduction: Metastasis and drug resistance contribute substantially to the poor prognosis of colorectal cancer (CRC) patients. However, the epigenetic regulatory mechanisms by which CRC develops metastatic and drug-resistant characteristics remain unclear. This study aimed to investigate the role...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857048/ https://www.ncbi.nlm.nih.gov/pubmed/31754405 http://dx.doi.org/10.7150/thno.36605 |
_version_ | 1783470687296421888 |
---|---|
author | Sun, Lina Fang, Ying Wang, Xin Han, Yanan Du, Feng Li, Cunxi Hu, Huaying Liu, Hao Liu, Qi Wang, Jing Liang, Junrong Chen, Ping Yang, Hongbin Nie, Yongzhan Wu, Kaichun Fan, Daiming Coffey, Robert J. Lu, Yuanyuan Zhao, Xiaodi Wang, Xin |
author_facet | Sun, Lina Fang, Ying Wang, Xin Han, Yanan Du, Feng Li, Cunxi Hu, Huaying Liu, Hao Liu, Qi Wang, Jing Liang, Junrong Chen, Ping Yang, Hongbin Nie, Yongzhan Wu, Kaichun Fan, Daiming Coffey, Robert J. Lu, Yuanyuan Zhao, Xiaodi Wang, Xin |
author_sort | Sun, Lina |
collection | PubMed |
description | Introduction: Metastasis and drug resistance contribute substantially to the poor prognosis of colorectal cancer (CRC) patients. However, the epigenetic regulatory mechanisms by which CRC develops metastatic and drug-resistant characteristics remain unclear. This study aimed to investigate the role of miR-302a in the metastasis and molecular-targeted drug resistance of CRC and elucidate the underlying molecular mechanisms. Methods: miR-302a expression in CRC cell lines and patient tissue microarrays was analyzed by qPCR and fluorescence in situ hybridization. The roles of miR-302a in metastasis and cetuximab (CTX) resistance were evaluated both in vitro and in vivo. Bioinformatic prediction algorithms and luciferase reporter assays were performed to identify the miR-302a binding regions in the NFIB and CD44 3'-UTRs. A chromatin immunoprecipitation assay was performed to examine NFIB occupancy in the ITGA6 promoter region. Immunoblotting was performed to identify the EGFR-mediated pathways altered by miR-302a. Results: miR-302a expression was frequently reduced in CRC cells and tissues, especially in CTX-resistant cells and patient-derived xenografts. The decreased miR-302a levels correlated with poor overall CRC patient survival. miR-302a overexpression inhibited metastasis and restored CTX responsiveness in CRC cells, whereas miR-302a silencing exerted the opposite effects. NFIB and CD44 were identified as novel targets of miR-302a. miR-302a inhibited the metastasis-promoting effect of NFIB that physiologically activates ITGA6 transcription. miR-302a restored CTX responsiveness by suppressing CD44-induced cancer stem cell-like properties and EGFR-mediated MAPK and AKT signaling. These results are consistent with clinical observations indicating that miR-302a expression is inversely correlated with the expression of its targets in CRC specimens. Conclusions: Our findings show that miR-302a acts as a multifaceted regulator of CRC metastasis and CTX resistance by targeting NFIB and CD44, respectively. Our study implicates miR-302a as a candidate prognostic predictor and a therapeutic agent in CRC. |
format | Online Article Text |
id | pubmed-6857048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-68570482019-11-21 miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44 Sun, Lina Fang, Ying Wang, Xin Han, Yanan Du, Feng Li, Cunxi Hu, Huaying Liu, Hao Liu, Qi Wang, Jing Liang, Junrong Chen, Ping Yang, Hongbin Nie, Yongzhan Wu, Kaichun Fan, Daiming Coffey, Robert J. Lu, Yuanyuan Zhao, Xiaodi Wang, Xin Theranostics Research Paper Introduction: Metastasis and drug resistance contribute substantially to the poor prognosis of colorectal cancer (CRC) patients. However, the epigenetic regulatory mechanisms by which CRC develops metastatic and drug-resistant characteristics remain unclear. This study aimed to investigate the role of miR-302a in the metastasis and molecular-targeted drug resistance of CRC and elucidate the underlying molecular mechanisms. Methods: miR-302a expression in CRC cell lines and patient tissue microarrays was analyzed by qPCR and fluorescence in situ hybridization. The roles of miR-302a in metastasis and cetuximab (CTX) resistance were evaluated both in vitro and in vivo. Bioinformatic prediction algorithms and luciferase reporter assays were performed to identify the miR-302a binding regions in the NFIB and CD44 3'-UTRs. A chromatin immunoprecipitation assay was performed to examine NFIB occupancy in the ITGA6 promoter region. Immunoblotting was performed to identify the EGFR-mediated pathways altered by miR-302a. Results: miR-302a expression was frequently reduced in CRC cells and tissues, especially in CTX-resistant cells and patient-derived xenografts. The decreased miR-302a levels correlated with poor overall CRC patient survival. miR-302a overexpression inhibited metastasis and restored CTX responsiveness in CRC cells, whereas miR-302a silencing exerted the opposite effects. NFIB and CD44 were identified as novel targets of miR-302a. miR-302a inhibited the metastasis-promoting effect of NFIB that physiologically activates ITGA6 transcription. miR-302a restored CTX responsiveness by suppressing CD44-induced cancer stem cell-like properties and EGFR-mediated MAPK and AKT signaling. These results are consistent with clinical observations indicating that miR-302a expression is inversely correlated with the expression of its targets in CRC specimens. Conclusions: Our findings show that miR-302a acts as a multifaceted regulator of CRC metastasis and CTX resistance by targeting NFIB and CD44, respectively. Our study implicates miR-302a as a candidate prognostic predictor and a therapeutic agent in CRC. Ivyspring International Publisher 2019-10-22 /pmc/articles/PMC6857048/ /pubmed/31754405 http://dx.doi.org/10.7150/thno.36605 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Sun, Lina Fang, Ying Wang, Xin Han, Yanan Du, Feng Li, Cunxi Hu, Huaying Liu, Hao Liu, Qi Wang, Jing Liang, Junrong Chen, Ping Yang, Hongbin Nie, Yongzhan Wu, Kaichun Fan, Daiming Coffey, Robert J. Lu, Yuanyuan Zhao, Xiaodi Wang, Xin miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44 |
title | miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44 |
title_full | miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44 |
title_fullStr | miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44 |
title_full_unstemmed | miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44 |
title_short | miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44 |
title_sort | mir-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting nfib and cd44 |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857048/ https://www.ncbi.nlm.nih.gov/pubmed/31754405 http://dx.doi.org/10.7150/thno.36605 |
work_keys_str_mv | AT sunlina mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT fangying mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT wangxin mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT hanyanan mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT dufeng mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT licunxi mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT huhuaying mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT liuhao mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT liuqi mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT wangjing mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT liangjunrong mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT chenping mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT yanghongbin mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT nieyongzhan mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT wukaichun mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT fandaiming mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT coffeyrobertj mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT luyuanyuan mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT zhaoxiaodi mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 AT wangxin mir302ainhibitsmetastasisandcetuximabresistanceincolorectalcancerbytargetingnfibandcd44 |